Stock Info Nets

Independent Financial Information Made Easy

Our AI creates

The Best Stock Graphs and Charts

Youtube Subscribe Blog GamificArt

The development of Artificial Intelligence (AI) is modifying the way investments are evaluated. We programmed an artificial intelligence (A.I.) to summarize the whole internet. Whether you’re trying to make money investing online, making financial decisions or just getting informed about Wall Street, this page is a way to get informed without reading hundred of pages. Our stock market summary graphs are produced using machine learning, an unbiased view to capture what internet is saying. Usually, the AI reads several hundred pages and summarize it to a short text and several charts.

June 01, 2023 8:11 (London Time)

Sangamo Therapeutics

Youtube Subscribe

...

Sector: Biotechnology
Ticker: SGMO
Sentiment: 0.9371
MarketCap: 217,768,891.0
High: 1.23 Low: 1.12

Open: 1.14 Close: 1.12 Change: -0.02

Can you guess what an AI found about Sangamo Therapeutics Stock.

How much time have you spent trying to decide whether investing in Sangamo Therapeutics? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Sangamo Therapeutics are: …

Concept Map

...

Semantic Network

...

Stock Summary

Sangamo Therapeutics, Inc. focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy.

Today's Summary

Sangamo Therapeutics Inc. (SGMO) stock price, quote & news - stock analysis. Share price: $9.75 (770.54% upside) Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shares tumbled by double digits in the first four days of trading this week. Shares of optical genome mapping company Bionano Genomics, Pacific Biosciences of California, and Sangamo. Sangamo Therapeutics Inc. (NASDAQ: SGMO) Is An Exciting Stock – Stocks Register. Sangamo therapeutics inc. (nasdaq: sgmo) is an exciting stock. Swiss National Bank Purchases 28,500 Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares of SGMO stock opened at $1.15 Wednesday.

Today's News

Sangamo Therapeutics Inc. (SGMO) stock price, quote & news - stock analysis. Share price: $9.75 (770.54% upside) Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shares tumbled by double digits in the first four days of trading this week. Shares of optical genome mapping company Bionano Genomics, Pacific Biosciences of California, and Sangamo. Sangamo Therapeutics Inc. (NASDAQ: SGMO) Is An Exciting Stock – Stocks Register. Sangamo therapeutics inc. (nasdaq: sgmo) is an exciting stock. Swiss National Bank Purchases 28,500 Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares of SGMO stock opened at $1.15 Wednesday.

Stock Profile

"Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California."

Keywords

The game is changing. There is a new strategy to evaluate Sangamo Therapeutics fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Sangamo Therapeutics are: Sangamo, Therapeutics, Inc, stock, SGMO, Shares, price, and the most common words in the summary are: therapeutic, sangamo, gene, stock, inc, therapy, market, . One of the sentences in the summary was: Share price: $9.75 (770.54% upside) Sangamo Therapeutics, Inc. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #therapeutic #sangamo #gene #stock #inc #therapy #market.

Read more →

Related Results

...
March 04, 2024 15:05 (London Time)

Sangamo Therapeutics

Sangamo Therapeutics, Inc. (nasdaq:SGMO) receives average rating of “hold” from analysts - defense world. sangamo therapeutics, inc. (NASDAQ:SGmo) R…
Sector: Biotechnology
Ticker: SGMO
Sentiment: 0.0
MarketCap: 195,081,678.0
High: 1.12 Low: 1.05

Open: 1.11 Close: 1.06 Change: -0.05

Read more →
...
June 01, 2023 8:11 (London Time)

Sangamo Therapeutics

Sangamo Therapeutics Inc. (SGMO) stock price, quote & news - stock analysis. Share price: $9.75 (770.54% upside) Sangamo Therapeutics, Inc. (NASDAQ:…
Sector: Biotechnology
Ticker: SGMO
Sentiment: 0.9371
MarketCap: 217,768,891.0
High: 1.23 Low: 1.12

Open: 1.14 Close: 1.12 Change: -0.02

Read more →
...
December 21, 2023 7:30 (London Time)

Sangamo Therapeutics

Sangamo Therapeutics (NASDAQ:SGMO) Receives Average Recommendation of “Hold” from Brokerages Posted by Defense World Staff on Dec 20th, 2023.
Sector: Biotechnology
Ticker: SGMO
Sentiment: -0.6369
MarketCap: 64,483,361.0
High: 0.42 Low: 0.36

Open: 0.4 Close: 0.36 Change: -0.04

Read more →